About Julie Miller, MD, PhD
Clinical Interests:
- Brain and spinal cord tumors
- Brain Metastases
- Brain tumors
- Glioblastoma
- low-grade gliomas
- Meningiomas
- Neuro-oncology
Treats:
- Adult
Locations
Mass General Cancer Center: Neuro-Oncology
55 Fruit St.
Yawkey Center for Outpatient Care
Boston, MA 02114
Phone: 617-724-8770
Phone: 877-518-2619
Medical Education
- M.D.; Ph.D., Stanford University School of Medicine
- Residency, Brigham and Women's Hospital
- Fellowship, Massachusetts General Hospital
American Board Certifications
- Neurology, American Board of Psychiatry & Neurology
- Neuro-Oncology, United Council for Neurologic Subspecialties
Accepted Insurance Plans
- Aetna
- Beech Street
- Blue Cross Blue Shield
- Blue Cross Blue Shield Medicare
- Cigna
- Commonwealth Care Alliance
- Coventry
- Fallon Health
- Harvard Pilgrim Health Care
- Humana
- Maine Community Health Options
- Mass General Brigham Health Plan
- MassHealth
- Medicaid CT
- Medicaid ME
- Medicaid NH
- Medicaid RI
- Medicare
- Medicare ACO
- Multiplan
- Senior Whole Health
- TriCare
- Tufts Health Plan
- United Health Care
- Wellpoint
- WellSense
- WellSense NH
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Research
Dr. Miller is interested in understanding the genetic and molecular mechanisms driving the development and progression of primary brain tumors, particularly IDH-mutant gliomas and glioblastoma. Her recent research has focused on the disruption of normal metabolism that is observed in IDH-mutant gliomas, with the goal of developing new drugs and treatment strategies to more effectively treat patients with these tumors. She has also been exploring the molecular changes that occur in IDH-mutant gliomas following chemotherapy exposure to better understand mechanisms of resistance and develop ways to prolong the clinical benefit of chemotherapy.
Publications
-
Selected Recent Publications:
Miller JJ, Cahill DP. MGMT promoter methylation and hypermutant recurrence in IDH mutant lower-grade glioma. Neuro Oncol. 2020 Nov 26.
Nagashima H, Lee CK, Tateishi K, Higuchi F, Subramanian M, Rafferty S, Melamed L, Miller JJ, Wakimoto H, Cahill DP. Poly(ADP-ribose) Glycohydrolase Inhibition Sequesters NAD+ to Potentiate the Metabolic Lethality of Alkylating Chemotherapy in IDH-Mutant Tumor Cells. Cancer Discov. 2020 Nov.
Miller JJ, Fink A, Banagis JA, Nagashima H, Subramanian M, Lee CK, Melamed L, Tummala SS, Tateishi K, Wakimoto H, Cahill DP. Sirtuin activation targets IDH-mutant tumors. Neuro Oncol. 2020 Jul 26.
Miller JJ, Loebel F, Juratli TA, Tummala SS, Williams EA, Batchelor TT, Arrillaga-Romany I, Cahill DP. Accelerated progression of IDH mutant glioma after first recurrence. Neuro Oncol. 2019 May 6.